Literature DB >> 23127467

β-Site amyloid precursor protein-cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau.

Amalia Tsolakidou1, Panagiotis Alexopoulos, Liang-Hao Guo, Timo Grimmer, Christine Westerteicher, Martina Kratzer, Meizi Jiang, Hideaki Bujo, Francesco Roselli, Maria Rosaria Leante, Paolo Livrea, Alexander Kurz, Robert Perneczky.   

Abstract

BACKGROUND: β-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) activity determines the rate of APP cleavage and is therefore the main driver of amyloid β production, which is a pathological hallmark of Alzheimer's disease (AD).
METHODS: The present study explored the correlation between BACE1 activity and cerebrospinal fluid (CSF) markers of APP metabolism and axonal degeneration in 63 patients with mild AD and 12 healthy control subjects.
RESULTS: In the AD group, positive correlations between BACE1 activity and soluble APP β, the APP sorting receptor sortilin-related receptor with A-type repeats (also known as SorLA or LR11), and tau were detected. BACE1 activity was not associated with amyloid β1-42 or soluble APP α concentrations in the AD group, and no associations between BACE1 activity and any of the protein concentrations were found in the control group.
CONCLUSION: Our results confirm the relevance of BACE1 and sortilin-related receptor with A-type repeats within the amyloid cascade and also provide a further piece of evidence for the link between amyloid and tau pathology in AD.
Copyright © 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23127467     DOI: 10.1016/j.jalz.2012.01.015

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  10 in total

1.  CSF sAPPα and sAPPβ levels in Alzheimer's Disease and Multiple Other Neurodegenerative Diseases: A Network Meta-Analysis.

Authors:  Wei Tang; Yan Wang; Juan Cheng; Jie Yao; Yu-You Yao; Qiang Zhou; Shi-He Guan
Journal:  Neuromolecular Med       Date:  2019-08-14       Impact factor: 3.843

2.  Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial.

Authors:  Boris Decourt; Denise Drumm-Gurnee; Jeffrey Wilson; Sandra Jacobson; Christine Belden; Sherye Sirrel; Michael Ahmadi; Holly Shill; Jessica Powell; Aaron Walker; Amanda Gonzales; Mimi Macias; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

Review 3.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

4.  Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease.

Authors:  Robert Perneczky; Panagiotis Alexopoulos
Journal:  Alzheimers Dement       Date:  2013-11-13       Impact factor: 21.566

Review 5.  The Role of SORL1 in Alzheimer's Disease.

Authors:  Rui-Hua Yin; Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2014-05-16       Impact factor: 5.590

6.  An exploratory study of the association between SORL1 polymorphisms and sporadic Alzheimer's disease in the Han Chinese population.

Authors:  Feng Zhang; Xiaowei Liu; Bailing Wang; Zaohuo Cheng; Xingfu Zhao; Jianzhong Zhu; Degang Wang; Ying Wang; Aiguo Dong; Pengpeng Li; Chunhui Jin
Journal:  Neuropsychiatr Dis Treat       Date:  2015-06-12       Impact factor: 2.570

Review 7.  Genes associated with Alzheimer's disease: an overview and current status.

Authors:  Mohan Giri; Man Zhang; Yang Lü
Journal:  Clin Interv Aging       Date:  2016-05-17       Impact factor: 4.458

Review 8.  Risk factor SORL1: from genetic association to functional validation in Alzheimer's disease.

Authors:  Olav M Andersen; Ina-Maria Rudolph; Thomas E Willnow
Journal:  Acta Neuropathol       Date:  2016-09-16       Impact factor: 17.088

9.  Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer's disease and associated with CSF-TAU and FDG-PET.

Authors:  Oliver Goldhardt; Inanna Warnhoff; Igor Yakushev; Ilijana Begcevic; Hans Förstl; Viktor Magdolen; Antoninus Soosaipillai; Eleftherios Diamandis; Panagiotis Alexopoulos; Timo Grimmer
Journal:  Transl Neurodegener       Date:  2019-08-27       Impact factor: 8.014

Review 10.  β-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification.

Authors:  Harald Hampel; Simone Lista; Eugeen Vanmechelen; Henrik Zetterberg; Filippo Sean Giorgi; Alessandro Galgani; Kaj Blennow; Filippo Caraci; Brati Das; Riqiang Yan; Andrea Vergallo
Journal:  Alzheimers Res Ther       Date:  2020-10-16       Impact factor: 6.982

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.